Left’s Newsletter

Left’s Newsletter

Share this post

Left’s Newsletter
Left’s Newsletter
Cipher Reports YE 2023 results; Epuris grows +10% Y/Y; company begins planning for commercialization of Terclara; CFO +49% Y/Y; Cash and Cash Equivalents +39% Y/Y offset by stock buybacks

Cipher Reports YE 2023 results; Epuris grows +10% Y/Y; company begins planning for commercialization of Terclara; CFO +49% Y/Y; Cash and Cash Equivalents +39% Y/Y offset by stock buybacks

Left's avatar
Left
Mar 14, 2024
∙ Paid
11

Share this post

Left’s Newsletter
Left’s Newsletter
Cipher Reports YE 2023 results; Epuris grows +10% Y/Y; company begins planning for commercialization of Terclara; CFO +49% Y/Y; Cash and Cash Equivalents +39% Y/Y offset by stock buybacks
Share

TL;DR - Product revenues continued to grow as a percent of the company’s total revenue with Epuris growing by 10%. Margins were maintained and Cipher continues to rapidly accumulate cash onto the balance sheet.

Key forward risk for current portfolio to track: Absorica LD launched in Canada during December of last year. If this eats into Epuris share, it will be visible starting next quarter.

Brief discussion of Terclara below

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Left Field
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share